Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

SELL
$1.0 - $1.45 $25,450 - $36,902
-25,450 Reduced 97.82%
566 $1,000
Q1 2024

May 07, 2024

SELL
$1.02 - $3.23 $594 - $1,883
-583 Reduced 2.19%
26,016 $33,000
Q4 2023

Feb 01, 2024

SELL
$1.72 - $3.18 $172 - $318
-100 Reduced 0.37%
26,599 $73,000
Q3 2023

Nov 07, 2023

BUY
$2.13 - $5.55 $1,488 - $3,879
699 Added 2.69%
26,699 $61,000
Q2 2023

Aug 07, 2023

BUY
$3.6 - $5.25 $93,600 - $136,500
26,000 New
26,000 $113,000
Q2 2022

Aug 04, 2022

SELL
$2.6 - $6.14 $64,833 - $153,107
-24,936 Reduced 98.96%
263 $1,000
Q1 2022

May 05, 2022

BUY
$5.08 - $9.81 $45 - $88
9 Added 0.04%
25,199 $144,000
Q4 2021

Feb 02, 2022

SELL
$8.55 - $111.89 $74,718 - $977,806
-8,739 Reduced 25.76%
25,190 $247,000
Q3 2021

Nov 02, 2021

SELL
$76.53 - $110.43 $803,029 - $1.16 Million
-10,493 Reduced 23.62%
33,929 $3.59 Million
Q2 2021

Aug 02, 2021

BUY
$85.37 - $114.1 $1.77 Million - $2.36 Million
20,722 Added 87.43%
44,422 $3.79 Million
Q4 2020

Feb 08, 2021

BUY
$79.58 - $152.45 $95,496 - $182,940
1,200 Added 5.33%
23,700 $3.32 Million
Q3 2020

Nov 05, 2020

BUY
$66.43 - $90.99 $13,286 - $18,198
200 Added 0.9%
22,500 $1.83 Million
Q2 2020

Aug 07, 2020

BUY
$44.04 - $80.69 $176,160 - $322,760
4,000 Added 21.86%
22,300 $1.6 Million
Q4 2019

Feb 05, 2020

SELL
$66.49 - $137.73 $139,629 - $289,233
-2,100 Reduced 10.29%
18,300 $1.75 Million
Q3 2019

Nov 07, 2019

BUY
$31.0 - $89.73 $80,600 - $233,298
2,600 Added 14.61%
20,400 $1.6 Million
Q2 2019

Aug 09, 2019

BUY
$36.0 - $44.73 $306,000 - $380,205
8,500 Added 91.4%
17,800 $771,000
Q4 2018

Feb 08, 2019

BUY
$31.59 - $62.65 $293,787 - $582,645
9,300 New
9,300 $486,000

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $108M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track New York State Common Retirement Fund Portfolio

Follow New York State Common Retirement Fund and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.